Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 HPV vaccination in women aged 24-45 years.

× No keyword cloud information.

3 in total

1. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

Authors: Ana Cecilia Rodríguez; Mark Schiffman; Rolando Herrero; Allan Hildesheim; Concepción Bratti; Mark E Sherman; Diane Solomon; Diego Guillén; Mario Alfaro; Jorge Morales; Martha Hutchinson; Hormuzd Katki; Li Cheung; Sholom Wacholder; Robert D Burk
Journal: J Natl Cancer Inst Date: 2010-02-15 Impact factor: 13.506

2. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Authors: Nubia Muñoz; Ricardo Manalastas; Punee Pitisuttithum; Damrong Tresukosol; Joseph Monsonego; Kevin Ault; Christine Clavel; Joaquin Luna; Evan Myers; Sara Hood; Oliver Bautista; Janine Bryan; Frank J Taddeo; Mark T Esser; Scott Vuocolo; Richard M Haupt; Eliav Barr; Alfred Saah
Journal: Lancet Date: 2009-06-01 Impact factor: 79.321

Review 3. Age-appropriate use of human papillomavirus vaccines in the U.S.

Authors: Philip E Castle; Barbara Fetterman; Israh Akhtar; Mujtaba Husain; Michael A Gold; Richard Guido; Andrew G Glass; Walter Kinney
Journal: Gynecol Oncol Date: 2009-05-22 Impact factor: 5.482

3 in total

4 in total

Review 4. Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women.

Authors: V Tsu; M Murray; S Franceschi
Journal: Br J Cancer Date: 2012-09-06 Impact factor: 7.640

4 in total

HPV vaccination in women aged 24-45 years.

1. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: critical role of duration of infection.

2. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial.

Review 3. Age-appropriate use of human papillomavirus vaccines in the U.S.

1. Invited commentary: the importance of prevalence in the effectiveness of a (bio)marker.

2. Loop electrosurgical excision procedure and risk of vaginal infections during pregnancy: an observational study.

Review 3. Cervical cancer: Can it be prevented?

Review 4. Human papillomavirus vaccination in low-resource countries: lack of evidence to support vaccinating sexually active women.